News Archives | Biolojic Design

Biolojic Design Appoints Neal Curran as Chief Business Officer

By webadmin@biolojic.com|2024-12-08T11:53:30+00:00December 8, 2024|News|0 Comments

Biolojic Design Joins Johnson & Johnson Innovation – JLABS

By webadmin@biolojic.com|2024-12-08T11:52:48+00:00December 8, 2024|News|0 Comments

Nektar Therapeutics Presents First Preclinical Data on NKTR-0165, a TNFR2 Agonist Antibody Being Developed for the Treatment of Inflammatory Diseases, at EULAR 2024

By webadmin@biolojic.com|2024-06-25T13:25:24+00:00June 12, 2024|News|0 Comments

Biolojic Design Enters into a Multi-Target Drug Discovery Collaboration with Merck KGaA, Darmstadt, Germany.

By webadmin@biolojic.com|2024-08-26T08:51:38+00:00June 3, 2024|News|0 Comments

Biolojic Design Announces that Nektar Therapeutics Has Exercised Its License Option to Develop an AI-Designed Agonistic Antibody Targeting TNFR2 for the Treatment of Autoimmune Diseases

By webadmin@biolojic.com|2024-06-05T12:40:33+00:00April 24, 2024|News|0 Comments

Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors

By Brandon Tilley|2023-12-31T10:55:19+00:00December 18, 2023|News|0 Comments

Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma

By Brandon Tilley|2023-12-31T10:51:58+00:00December 14, 2023|News|0 Comments

The Logical Song: Biolojic Design Reimagines Antibodies into “Smart” Therapeutics

By Brandon Tilley|2023-07-18T14:26:23+00:00August 23, 2022|News|0 Comments

First-Ever Computationally Designed Antibody, Created by Biolojic Design, Entering Human Clinical Trial In Cancer Patients

By Brandon Tilley|2023-06-22T18:15:25+00:00April 5, 2022|News|0 Comments

Lilly and Biolojic Design Announce Research Collaboration to Discover and Develop Antibody Therapies for Diabetes

By Brandon Tilley|2023-06-22T18:16:10+00:00March 8, 2021|News|0 Comments